Alpha Cognition, Inc. (NASDAQ: ACOG) announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study evaluating ZUNVEYL (benzgalantamine) in patients with mild to moderate Alzheimer's disease.

RESOLVE is a multicenter study designed to assess the tolerability profile of ZUNVEYL in routine clinical practice. The study will collect safety and tolerability data and explore changes in Alzheimer's disease-related neuropsychiatric symptoms in an outpatient setting. The study will also monitor adverse events, treatment persistence, and discontinuation rates.

The study is expected to enroll approximately 150 patients across multiple clinical sites. Patient enrollment is expected to continue through the second quarter of 2027, with topline results anticipated following completion of enrollment and study follow-up.

"The approval of ZUNVEYL marked an important step forward, but our responsibility to patients and healthcare providers does not end with approval," said Kurt Grady, Vice President of Medical Affairs at Alpha Cognition. "RESOLVE reflects our commitment to continuing to learn from real-world clinical practice and to generating evidence that helps physicians make informed treatment decisions for patients living with Alzheimer's disease."

ZUNVEYL is an FDA-approved acetylcholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. The information is based on a press release from Alpha Cognition.